The First dose of the Oxford University’s COVID-19 vaccine will be directed by six trial participants at the Bharti the Vidyapeeth Medical College and Hospital in Pune on Wednesday. Hospital screened the individuals including three men and three women for antibodies.
Three tests have been conducted :
This vaccine is known as Covishield in India. This is developed by AstraZeneca and Oxford University and British-Swedish pharmaceutical firm. World’s largest The Pune-based Serum Institute began the second phase of the medical trial of the vaccine on Tuesday.
The Serum Institute is conducting trials in India with the corporation of the Indian Council of Medical Research.
1,600 people will be enrolled for the second and third phase of the experimental trials. This initiative will be taken to assess the vaccine’s safety and its side-effects.
Drug Controller General of India granted permissions to the institute for conducting phase two and three human trials.
5,000 people would be administered the vaccine in Pune and Mumbai till the end of August as part of the trials. The trials will last over two months.
“We are enrolling six persons for the trial, and the screening process is underway,” Sanjay Lalwani, medical director of Bharati Vidyapeeth Medical College said. “
Bharat Biotech for Covaxin and Zydus Cadalia for ZyCoV-D and Zydus Cadila for initiated the first and the second phase of clinical trials last month.
Over 100 vaccine is being developed in the world to tackle the coronavirus pandemic, according to Reuters. The World Health Organization data displays at least four vaccines are in phase three trials, including those from China and Britain.